BioMarin Pharmaceutical bmrn.com


Public lists: Pharma Startups (6570)

BioMarin (NASDAQ: BMRN) develops and commercializes biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that address currently unmet medical needs; suggest a clear-cut development profile; and provide an opportunity to be first-to-market. In addition, most of BioMarin's therapeutic products qualify for fast-track designation and orphan drug status from the U.S. Food and Drug Administration (FDA), which, if granted, would provide these products accelerat...Show all

BioMarin (NASDAQ: BMRN) develops and commercializes biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that address currently unmet medical needs; suggest a clear-cut development profile; and provide an opp...Show all

Company (Alive / Active)

Phone: 415-506-6700

Fax: 415-382-7889

770 Lindaro St.

San Rafael, 94901
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
BioMarin Pharmaceutical $66M May 7, 2001
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related BioMarin Pharmaceutical Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Allos Therapeutics

Westminster, Colorado, United States
AcquiredAllos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or ...Show allLogin to see details

Cardioxyl Pharmaceuticals

Chapel Hill, North Carolina, United States
AcquiredCardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed solutions in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinic...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Processes of synthesizing dihydropyridophthalazinone derivatives Jun 02, 2014 Mar 27, 2018 Patent
Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (mps) vi and iva Apr 12, 2016 Mar 13, 2018 Patent
Histone deacetylase inhibitors Oct 28, 2016 Mar 06, 2018 Patent
Use of c-type natriuretic peptide variants to treat skeletal dysplasia Aug 01, 2016 Mar 06, 2018 Patent
Variants of c-type natriuretic peptide Jan 23, 2015 Feb 13, 2018 Patent
See all 91 patents